Exact Sciences
We're hiring — explore open roles below and apply in a few clicks.
Location
Headquarters: Madison, Wisconsin, United States, North America
Region: Wisconsin
Country: US
Continent: North America
About
Exact Sciences is a cancer diagnostics company focused on prevention, early detection, and therapy guidance. The company develops and provides diagnostic tests that assess hereditary risks, screen for cancer presence, and analyze genomic alterations to guide treatment, serving patients, providers, researchers, and healthcare systems. Headquartered in Madison, Wisconsin, Exact Sciences collaborates with laboratories, institutions, and policy makers to advance cancer care globally.
Exact Sciences is a molecular diagnostics company that develops and provides tests for cancer prevention, early detection, and therapy guidance. Its products, including the Cologuard screening test, serve healthcare providers, patients, and researchers to assess hereditary risks and analyze genomic alterations.
Exact Sciences Corp.
1995
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Public Company
1700000000
over-1b
ipo
EXAS
nasdaq
Investors
Founders
Anthony P. Shuber
Stanley Lapidus
Leadership
Molly Dowd — Senior Program Manager, Customer Experience
Lindsay Johnson — HR Operations Specialist
Graham Lidgard — Senior Vice President R&D and Chief Science Officer
Scott Johnson — Senior Vice President, Clinical & Regulatory Affairs
Steve Shak — Chief Medical Officer
Ana Hooker — Senior Vice President, Operations
Technology Stack
Products
Cologuard® test: A noninvasive stool-based screening test for colorectal cancer in adults aged 45 and older at average risk.
Cologuard Plus™ test: A stool-based screening test for colorectal cancer in adults aged 45 and older at average risk, building on the original Cologuard® test.
Oncodetect™ test: A blood-based tumor-informed test that detects circulating tumor DNA to monitor cancer recurrence and guide therapy decisions for solid tumor patients.
Oncoguard® Liver test: A blood test for surveillance of hepatocellular carcinoma in patients with cirrhosis or chronic hepatitis B.
Riskguard® test: A blood or saliva test that identifies hereditary risk for multiple cancers and informs treatment decisions.
Oncotype DX Breast Recurrence Score® test: A tumor tissue test that predicts the likelihood of breast cancer recurrence and potential chemotherapy benefit in early-stage breast cancer patients.
Funding rounds
Acquired · (2025-06-20)
Post Ipo Debt · $620.7M · (2024-04-11)
Post Ipo Debt · $500M · (2023-02-23)
Connect
Connect
Open positions(3)
- CAD Designer, Equipment & Automation - 1st shiftFull-timeHybridUS - WI - Madison64,000–105,000 / Year
- Bioinformatician II: Tuesday - SaturdayPremiumFull-timeWork from OfficeUS - WI - Madison84,000–138,000 / Year
- Lead AI Platform EngineerPremiumFull-timeWork from OfficeUS - WI - Madison151,000–276,000 / Year